{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T18:10:36Z","timestamp":1785435036165,"version":"3.56.0"},"reference-count":114,"publisher":"Informa UK Limited","issue":"6","license":[{"start":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T00:00:00Z","timestamp":1660089600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Human Vaccines & Immunotherapeutics"],"published-print":{"date-parts":[[2022,11,30]]},"DOI":"10.1080\/21645515.2022.2099142","type":"journal-article","created":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T19:22:36Z","timestamp":1660159356000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Immunogenicity and safety of MenACWY-TT, a quadrivalent meningococcal tetanus toxoid conjugate vaccine recently licensed in the United States for individuals \u22652 years of age"],"prefix":"10.1080","volume":"18","author":[{"given":"Gary S.","family":"Marshall","sequence":"first","affiliation":[{"name":"Division of Pediatric Infectious Diseases, Norton Children\u2019s and University of Louisville School of Medicine, Louisville, KY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen I.","family":"Pelton","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Boston University School of Medicine, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corwin A.","family":"Robertson","sequence":"additional","affiliation":[{"name":"US Medical Affairs, Sanofi, Discovery Drive, Swiftwater, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Oster","sequence":"additional","affiliation":[{"name":"Global Medical Affairs, Sanofi, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,8,10]]},"reference":[{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.12.062"},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-61779-346-2_1"},{"key":"e_1_3_5_4_1","first-page":"207","volume-title":"Epidemiology and prevention of vaccine-preventable diseases","author":"Mbaeyi S","year":"2015","unstructured":"Mbaeyi S, Duffy J, and McNamara LA. Meningococcal disease. In: Hamborsky J, Kroger A, Wolfe S, editors. Epidemiology and prevention of vaccine-preventable diseases. Washington DC: Public Health Foundation. 207\u2013224; 2015."},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.04.070"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.5802\/crbiol.56"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2020-237366"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0107486"},{"key":"e_1_3_5_9_1","volume-title":"Meningococcemia. StatPearls","author":"Siddiqui JA","year":"2021","unstructured":"Siddiqui JA, Ameer MA, Gulick PG. Meningococcemia. StatPearls. Treasure Island (FL): StatPearls Publishing LLC.; 2021."},{"key":"e_1_3_5_10_1","volume-title":"Meningococcal meningitis - Fact sheet","author":"World Health Organization (WHO)","year":"2018","unstructured":"World Health Organization (WHO). Meningococcal meningitis - Fact sheet. Geneva, Switzerland: World Health Organization (WHO); 2018."},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jadohealth.2016.04.012"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2017.1258308"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix993"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.7189\/jogh.09.010409"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.04.036"},{"key":"e_1_3_5_17_1","volume-title":"Surveillance Atlas of Infectious Diseases - Invasive Meningococcal Disease","author":"European Center for Disease Prevention and Control","year":"2017","unstructured":"European Center for Disease Prevention and Control. Surveillance Atlas of Infectious Diseases - Invasive Meningococcal Disease. Solna, Sweden: European Center for Disease Prevention and Control; 2017."},{"key":"e_1_3_5_18_1","volume-title":"Meningococcal group W (MenW) immunisation advised for 14 to 18 year-olds","author":"Public Health England","year":"2015","unstructured":"Public Health England. Meningococcal group W (MenW) immunisation advised for 14 to 18 year-olds. London, UK: Public Health England; 2015."},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2018.23.16.18-00158"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2018.1532248"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03502-9"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmaid.2018.05.003"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy257"},{"key":"e_1_3_5_24_1","first-page":"116","article-title":"Massive diarrhoea and sepsis due to an infection with Neisseria meningitidis serogroup W","volume":"77","author":"Houweling BM","year":"2019","unstructured":"Houweling BM, van Meurs SJ, Versluis J, Grewal S, Verkaik NJ, van den Akker JPC. Massive diarrhoea and sepsis due to an infection with Neisseria meningitidis serogroup W. Neth J Med. 2019;77:116\u2013118.","journal-title":"Neth J Med"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1177\/1751143718794127"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268819002152"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz578"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.04.020"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1086\/649209"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e31820a8b3c"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2020.1990"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofv117"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6924a2"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e3180cc2c25"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1586\/erv.10.3"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms8111675"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2018.1451810"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/femspd\/ftx033"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-020-09946-1"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-019-0254-1"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.rr6909a1"},{"key":"e_1_3_5_43_1","volume-title":"Menactra\u00ae, Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine Solution for Intramuscular Injection","author":"Sanofi Pasteur","year":"2016","unstructured":"Sanofi Pasteur. Menactra\u00ae, Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine Solution for Intramuscular Injection. Swiftwater, PA: Sanofi Pasteur Inc; 2016."},{"key":"e_1_3_5_44_1","volume-title":"MENVEO [Meningococcal (Groups A, C, Y, and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine]","author":"GSK Vaccines Srl","year":"2020","unstructured":"GSK Vaccines Srl. MENVEO [Meningococcal (Groups A, C, Y, and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine]. Bellaria-Rosia, Sovicille, Italy: GSK Vaccines, Srl; 2020."},{"key":"e_1_3_5_45_1","volume-title":"MenQuadfi\u2122, Meningococcal (Groups A, C, Y, W) Conjugate Vaccine Solution for Intramuscular Injection","author":"Sanofi Pasteur I","year":"2020","unstructured":"Sanofi Pasteur I. MenQuadfi\u2122, Meningococcal (Groups A, C, Y, W) Conjugate Vaccine Solution for Intramuscular Injection. Swiftwater, PA: Sanofi Pasteur, Inc; 2020."},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.02.030"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.07.039"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2016-2193"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000126297.28952.f8"},{"key":"e_1_3_5_50_1","volume-title":"Exploratory Trial to Evaluate the Safety and Immunogenicity of Menactra\u00ae and Menomune\u00ae Vaccines in Subjects \u2265 56 Years (NCT00874549)","author":"United States National Library of Medicine","year":"2009","unstructured":"United States National Library of Medicine. Exploratory Trial to Evaluate the Safety and Immunogenicity of Menactra\u00ae and Menomune\u00ae Vaccines in Subjects \u2265 56 Years (NCT00874549). Bethesda, MD: National Institutes of Health; 2009."},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2010.03.017"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00099-14"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2015.07.003"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e318268dfe4"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e31823dce5c"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000000930"},{"key":"e_1_3_5_57_1","first-page":"1023","article-title":"Guillain-Barr\u00e9 syndrome among recipients of Menactra meningococcal conjugate vaccine\u2013United States, June-July 2005","volume":"54","author":"Centers for Disease Control and Prevention","year":"2005","unstructured":"Centers for Disease Control and Prevention. Guillain-Barr\u00e9 syndrome among recipients of Menactra meningococcal conjugate vaccine\u2013United States, June-July 2005. MMWR Morb Mortal Wkly Rep 2005;54:1023\u20131025.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.10.050"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3321"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3353"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir960"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit222"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2016-2084"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.09.032"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.02.107"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6506a4"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40290-020-00362-9"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000001696"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10719-022-10050-2"},{"key":"e_1_3_5_70_1","volume-title":"Meningococcal (Groups A, C, Y, W) Conjugate Vaccine - BLA Approval","author":"United States Food and Drug Administration (FDA)","year":"2020","unstructured":"United States Food and Drug Administration (FDA). Meningococcal (Groups A, C, Y, W) Conjugate Vaccine - BLA Approval. Rockville, MD: United States Food and Drug Administration (FDA); 2020."},{"key":"e_1_3_5_71_1","volume-title":"Meningococcal (Groups A, C, Y, W) Conjugate Vaccine - BLA Clinical Review Memorandum","author":"United States Food and Drug Administration (FDA)","year":"2020","unstructured":"United States Food and Drug Administration (FDA). Meningococcal (Groups A, C, Y, W) Conjugate Vaccine - BLA Clinical Review Memorandum. Rockville, MD: United States Food and Drug Administration (FDA); 2020."},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000002832"},{"key":"e_1_3_5_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.03.017"},{"key":"e_1_3_5_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.06.013"},{"key":"e_1_3_5_75_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2020.1733867"},{"key":"e_1_3_5_76_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2020.1733868"},{"key":"e_1_3_5_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.04.067"},{"key":"e_1_3_5_78_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268821000698"},{"key":"e_1_3_5_79_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2021.1902701"},{"key":"e_1_3_5_80_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268821000261"},{"key":"e_1_3_5_81_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2020.1733869"},{"key":"e_1_3_5_82_1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2021.1964962"},{"key":"e_1_3_5_83_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.129.6.1307"},{"key":"e_1_3_5_84_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2019.1593082"},{"key":"e_1_3_5_85_1","volume-title":"Vaccines and Related Biological Products Advisory Committee: FDA Briefing Document - Use of Serum Bactericidal Antibody as an Immunological Correlate for Demonstrating Effectiveness of Meningococcal Conjugate Vaccines (Serogroups A, C, Y, W-135) Administered to Children Less Than 2 Years of Age","author":"United States Food and Drug Administration (FDA)","year":"2011","unstructured":"United States Food and Drug Administration (FDA). Vaccines and Related Biological Products Advisory Committee: FDA Briefing Document - Use of Serum Bactericidal Antibody as an Immunological Correlate for Demonstrating Effectiveness of Meningococcal Conjugate Vaccines (Serogroups A, C, Y, W-135) Administered to Children Less Than 2 Years of Age. Rockville, MD: United States Food and Drug Administration (FDA); 2011."},{"key":"e_1_3_5_86_1","volume-title":"MenQuadfi\u2122 - Summary Basis for Regulatory Action, April 22, 2020","author":"United States Food and Drug Administration (FDA)","year":"2020","unstructured":"United States Food and Drug Administration (FDA). MenQuadfi\u2122 - Summary Basis for Regulatory Action, April 22, 2020. Rockville, MD: United States Food and Drug Administration (FDA); 2020."},{"key":"e_1_3_5_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.04.034"},{"key":"e_1_3_5_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.02.045"},{"key":"e_1_3_5_89_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/173.4.1014"},{"key":"e_1_3_5_90_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2018.1452576"},{"key":"e_1_3_5_92_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40471-018-0170-z"},{"key":"e_1_3_5_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2020.05.079"},{"key":"e_1_3_5_94_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.06.026"},{"key":"e_1_3_5_95_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268821000698"},{"key":"e_1_3_5_96_1","first-page":"252","volume-title":"20th International Pathogenic Neisseria Conference (IPNC)","author":"Cornish M","year":"2016","unstructured":"Cornish M, Pina LM, Jezorwski J, DaCosta X, Rehm C, Dhingra MS Safety and immunogenicity of an investigational quadrivalent meningococcal conjugate vaccine (MenACYW-TT) administered to infants and toddlers (Abstract ID: 162). 20th International Pathogenic Neisseria Conference (IPNC). Manchester, United Kingdom, 2016:252."},{"key":"e_1_3_5_97_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.11.045"},{"key":"e_1_3_5_98_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.06.030"},{"key":"e_1_3_5_99_1","first-page":"E107","article-title":"Hexavalent vaccines: characteristics of available products and practical considerations from a panel of Italian experts","volume":"59","author":"Orsi A","year":"2018","unstructured":"Orsi A, Azzari C, Bozzola E, Chiamenti G, Chirico G, Esposito S, Francia F, Lopalco P, Prato R, Russo R, et al. Hexavalent vaccines: characteristics of available products and practical considerations from a panel of Italian experts. J Prev Med Hyg. 2018;59:E107\u2013e19.","journal-title":"J Prev Med Hyg"},{"key":"e_1_3_5_100_1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2020.1873770"},{"key":"e_1_3_5_101_1","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2016.21.45.30395"},{"key":"e_1_3_5_102_1","first-page":"217","article-title":"Outbreak of meningococcal disease associated with an elementary school \u2013 Oklahoma, March 2010","volume":"61","author":"United States Centers for Disease Control and Prevention (CDC)","year":"2012","unstructured":"United States Centers for Disease Control and Prevention (CDC). Outbreak of meningococcal disease associated with an elementary school \u2013 Oklahoma, March 2010. MMWR Morb Mortal Wkly Rep 2012;61:217\u2013221.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_3_5_103_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.medmal.2019.10.003"},{"key":"e_1_3_5_104_1","volume-title":"MenQuadfi, Meningococcal (Groups A, C, Y, W) Conjugate Vaccine Solution for Intramuscular Injection - Prescribing Information","author":"United States Food and Drug Administration (FDA)","year":"2020","unstructured":"United States Food and Drug Administration (FDA). MenQuadfi, Meningococcal (Groups A, C, Y, W) Conjugate Vaccine Solution for Intramuscular Injection - Prescribing Information. Rockville, MD: United States Food and Drug Administration (FDA); 2020."},{"key":"e_1_3_5_105_1","doi-asserted-by":"publisher","DOI":"10.4155\/cli.12.52"},{"key":"e_1_3_5_106_1","doi-asserted-by":"publisher","DOI":"10.1006\/biol.2000.0253"},{"key":"e_1_3_5_107_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2022.01.050"},{"key":"e_1_3_5_108_1","volume-title":"A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers (MET39; NCT01049035)","author":"United States National Library of Medicine","year":"2020","unstructured":"United States National Library of Medicine. A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers (MET39; NCT01049035). Bethesda, MD: National Institutes of Health; 2020."},{"key":"e_1_3_5_109_1","volume-title":"Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered with Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe (MET58; NCT03547271)","author":"United States National Library of Medicine","year":"2020","unstructured":"United States National Library of Medicine. Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered with Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe (MET58; NCT03547271). Bethesda, MD: National Institutes of Health; 2020."},{"key":"e_1_3_5_110_1","volume-title":"Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers (MET41; NCT03673462)","author":"United States National Library of Medicine","year":"2020","unstructured":"United States National Library of Medicine. Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers (MET41; NCT03673462). Bethesda, MD: National Institutes of Health; 2020."},{"key":"e_1_3_5_111_1","volume-title":"Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US (MET42; NCT03537508)","author":"United States National Library of Medicine","year":"2021","unstructured":"United States National Library of Medicine. Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US (MET42; NCT03537508). Bethesda, MD: National Institutes of Health; 2021."},{"key":"e_1_3_5_112_1","volume-title":"Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers (MET61; NCT03691610)","author":"United States National Library of Medicine","year":"2021","unstructured":"United States National Library of Medicine. Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers (MET61; NCT03691610). Bethesda, MD: National Institutes of Health; 2021."},{"key":"e_1_3_5_113_1","volume-title":"Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers When Administered Concomitantly with Routine Pediatric Vaccines in the United Kingdom (MET52; NCT03632720)","author":"United States National Library of Medicine","year":"2021","unstructured":"United States National Library of Medicine. Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers When Administered Concomitantly with Routine Pediatric Vaccines in the United Kingdom (MET52; NCT03632720). Bethesda, MD: National Institutes of Health; 2021."},{"key":"e_1_3_5_114_1","volume-title":"Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers in the Russian Federation and Mexico (MET33; NCT03630705)","author":"United States National Library of Medicine","year":"2021","unstructured":"United States National Library of Medicine. Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers in the Russian Federation and Mexico (MET33; NCT03630705). Bethesda, MD: National Institutes of Health; 2021."},{"key":"e_1_3_5_115_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab466.206"},{"key":"e_1_3_5_116_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab466.1240"},{"key":"e_1_3_5_117_1","volume-title":"Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine When Administered Alone or Concomitantly with a Licensed Meningococcal Serogroup B Vaccine, in Participants Who Received Primary Quadrivalent Meningococcal Conjugate Vaccine (MCV4) (MET59; NCT04084769)","author":"United States National Library of Medicine","year":"2021","unstructured":"United States National Library of Medicine. Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine When Administered Alone or Concomitantly with a Licensed Meningococcal Serogroup B Vaccine, in Participants Who Received Primary Quadrivalent Meningococcal Conjugate Vaccine (MCV4) (MET59; NCT04084769). Bethesda, MD: National Institutes of Health; 2021."},{"key":"e_1_3_5_118_1","volume-title":"Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine in Older Adults Who Received a Primary Vaccination (3 or More Years Earlier) in Study MET49 (MEQ00066; NCT04142242)","author":"United States National Library of Medicine","year":"2019","unstructured":"United States National Library of Medicine. Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine in Older Adults Who Received a Primary Vaccination (3 or More Years Earlier) in Study MET49 (MEQ00066; NCT04142242). Bethesda, MD: National Institutes of Health; 2019."}],"updated-by":[{"DOI":"10.1080\/21645515.2022.2133330","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T00:00:00Z","timestamp":1666137600000}}],"container-title":["Human Vaccines & Immunotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/21645515.2022.2099142","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T17:41:08Z","timestamp":1737049268000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/21645515.2022.2099142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,10]]},"references-count":114,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,11,30]]}},"alternative-id":["10.1080\/21645515.2022.2099142"],"URL":"https:\/\/doi.org\/10.1080\/21645515.2022.2099142","relation":{"correction":[{"id-type":"doi","id":"10.1080\/21645515.2022.2133330","asserted-by":"object"}]},"ISSN":["2164-5515","2164-554X"],"issn-type":[{"value":"2164-5515","type":"print"},{"value":"2164-554X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,10]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-04-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-14","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2099142"}}